Page 1

SARTORIUS Press Release Göttingen , July 21 , 2021 Sartorius continues on its fast growth trajectory significant double - digit increases in sales and earnings . " " Order intake up 82.4 percent ; sales revenue up 60.1 percent ; underlying EBITDA margin 34.1 percent Dynamic organic growth in the core businesses of both divisions , bolstered by added momentum from pandemic - related activity and gains contributed by acquisitions ■ Forecast for 2021 raised yet again at the beginning of July The life science Group Sartorius has continued on its fast growth trajectory , closing the first half of 2021 with significant double - digit increases in both sales revenue and order intake¹ . " In the first six months of the year , we have seen unabated high demand for innovative technologies used in the development and production of biopharmaceuticals . Orders from customers who manufacture coronavirus vaccines and coronavirus test kits have played an additional important , though not dominant , role in this respect . The acquisitions closed in 2020 also are performing well and have added positive momentum . Our most recent acquisition of a majority stake in CellGenix , a leading global supplier of GMP - grade cell culture components , enables us to provide our customers with even more comprehensive support in moving their drug candidates quickly and efficiently through the various steps of drug development so that innovative therapies reach patients faster , " said Executive Board Chairman and CEO Joachim Kreuzburg . " Due to the ongoing expansion of our production facilities worldwide , we are well prepared to respond to the high demand expected to continue , and recruitment of additional employees is continuing at full speed . As communicated at the beginning of July , we significantly raised our sales and earnings forecast for the full year yet again though forecasts are currently subject to above - average uncertainty due to the various pandemic - related effects , " emphasized Kreuzburg . Business development of the Group Based on constant currencies , Group sales revenue rose 60.1 percent to around 1,629 million euros ( reported : +54.2 percent ) . The majority of this growth was generated based on the strong organic expansion of the core businesses of both divisions in all regions . Acquisitions² added a good 8 percentage points to the increase in sales revenue , and the growth related to the development and production of vaccines and coronavirus test kits was about 22 percentage points . Order intake¹ grew even more dynamically , rising to 2,179 million euros ( +82.4 percent in constant currencies of which around 27 percentage points were attributable to the coronavirus pandemic and around 10 percentage points to acquisitions ; reported : +75.0 percent ) . 1 | 6